HCS Pharma announces the closure of the “MIMLIVERonChip” project, funded by the French National Research Agency (ANR, project ANR 19 CE19-0020) and coordinated by BMBI Biomechanics and Bioengineering joint research unit (UTC/ CNRS), headed by Dr Cécile Legallais, CNRS research director. This project led to the publication of Taha Messelmani’s thesis at Compiègne University of Technology (UTC) on the major advances made in the development of a liver-on-a-chip model using HCS Pharma’s BIOMIMESYS® Hydroscaffold™ technology. This project presents a promising advance in limiting the use of animals in the drug discovery process.

Primary Human Hepatocytes whithin BIOMIMESYS® in BMBI’s microfluidic system

BIOMIMESYS®, as an innovative and reliable 3D cell culture system, will be an important add-on for current and future drug discovery platforms in the pharmaceutical industry because adapted to high throughput formats and as a reproducible matrix. Allowing the model different aspects of tissue environment, BIOMIMESYS® product range also now has the advantage to be animal-free, therefore even more adapted to 3Rs than ever.

The press release (in French) can be found and downloaded here; special thanks to La Gazette du Laboratoire and CNRS Hauts-De-France to spread the word! Please feel free to contact us if you want to know how to use BIOMIMESYS® in microfluidic systems.


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.